ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
- PMID: 15731348
- PMCID: PMC553328
- DOI: 10.1073/pnas.0409773102
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
Abstract
Therapies that target the EGF receptor (EGFR), such as gefitinib (IRESSA), are effective in a subset of patients with advanced non-small cell lung cancer (NSCLC). The differences in intracellular signaling networks between gefitinib-sensitive and -resistant NSCLCs remain poorly understood. In this study, we observe that gefitinib reduces phospho-Akt levels only in NSCLC cell lines in which it inhibits growth. To elucidate the mechanism underlying this observation, we compared immunoprecipitates of phosphoinositide 3-kinase (PI3K) between gefitinib-sensitive and -resistant NSCLC cell lines. We observe that PI3K associates with ErbB-3 exclusively in gefitinib-sensitive NSCLC cell lines. Gefitinib dissociates this complex, thereby linking EGFR inhibition to decreased Akt activity. In contrast, gefitinib-resistant cells do not use ErbB-3 to activate the PI3K/Akt pathway. In fact, abundant ErbB-3 expression is detected only in gefitinib-sensitive NSCLC cell lines. Two gefitinib-sensitive NSCLC cell lines with endogenous distinct activating EGFR mutations (L858R and Del747-749), frequently observed in NSCLC patients who respond to gefitinib, also use ErbB-3 to couple to PI3K. Down-regulation of ErbB-3 by means of short hairpin RNA leads to decreased phospho-Akt levels in the gefitinib-sensitive NSCLC cell lines, Calu-3 (WT EGFR) and H3255 (L858R EGFR), but has no effect on Akt activation in the gefitinib-resistant cell lines, A549 and H522. We conclude that ErbB-3 is used to couple EGFR to the PI3K/Akt pathway in gefitinib-sensitive NSCLC cell lines harboring WT and mutant EGFRs.
Figures
![Fig. 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/553328/bin/zpq0060572850001.gif)
![Fig. 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/553328/bin/zpq0060572850002.gif)
![Fig. 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/553328/bin/zpq0060572850003.gif)
![Fig. 4.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/553328/bin/zpq0060572850004.gif)
![Fig. 5.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/553328/bin/zpq0060572850005.gif)
Similar articles
-
Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.Clin Lung Cancer. 2013 Jul;14(4):322-32. doi: 10.1016/j.cllc.2012.12.001. Epub 2013 Jan 16. Clin Lung Cancer. 2013. PMID: 23332287 Review.
-
An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).Int J Mol Med. 2007 Jul;20(1):3-10. Int J Mol Med. 2007. PMID: 17549382 Review.
-
Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.BMC Cancer. 2006 Dec 6;6:277. doi: 10.1186/1471-2407-6-277. BMC Cancer. 2006. PMID: 17150102 Free PMC article.
-
HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.Cancer Res. 2005 May 15;65(10):4253-60. doi: 10.1158/0008-5472.CAN-04-2748. Cancer Res. 2005. PMID: 15899817
-
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.Cancer Res. 2004 Oct 15;64(20):7241-4. doi: 10.1158/0008-5472.CAN-04-1905. Cancer Res. 2004. PMID: 15492241
Cited by
-
SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs.Acta Pharmacol Sin. 2024 Apr;45(4):857-866. doi: 10.1038/s41401-023-01221-4. Epub 2024 Jan 10. Acta Pharmacol Sin. 2024. PMID: 38200149
-
Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: a narrative review.Transl Cancer Res. 2023 Dec 31;12(12):3764-3778. doi: 10.21037/tcr-23-956. Epub 2023 Nov 24. Transl Cancer Res. 2023. PMID: 38192990 Free PMC article. Review.
-
Therapeutic target biomarkers of patient-derived xenograft models of gastric-type cervical adenocarcinoma.Gynecol Oncol Rep. 2023 Nov 14;50:101302. doi: 10.1016/j.gore.2023.101302. eCollection 2023 Dec. Gynecol Oncol Rep. 2023. PMID: 38054200 Free PMC article.
-
Peptide G-Protein-Coupled Receptors and ErbB Receptor Tyrosine Kinases in Cancer.Biology (Basel). 2023 Jul 4;12(7):957. doi: 10.3390/biology12070957. Biology (Basel). 2023. PMID: 37508387 Free PMC article. Review.
-
Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer.J Clin Invest. 2023 Jan 17;133(2):e160330. doi: 10.1172/JCI160330. J Clin Invest. 2023. PMID: 36647832 Free PMC article.
References
-
- Breathnach, O. S., Freidlin, B., Conley, B., Green, M. R., Johnson, D. H., Gandara, D. R., O'Connell, M., Shepherd, F. A. & Johnson, B. E. (2001) J. Clin. Oncol. 19, 1734-1742. - PubMed
-
- Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J. & Johnson, D. H. (2002) N. Engl. J. Med. 346, 92-98. - PubMed
-
- Laskin, J. J. & Sandler, A. B. (2004) Cancer Treat. Rev. 30, 1-17. - PubMed
-
- Riese, D. J., II, & Stern, D. F. (1998) Bioessays 20, 41-48. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous